111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Key Points

• 111 Capital has acquired a new stake in Halozyme Therapeutics, purchasing 13,238 shares valued at approximately $689,000 in the second quarter.
• Insider selling activity included CEO Helen Torley and CFO Nicole Labrosse, who sold 20,000 shares each, indicating a 2.65% and 45.14% decrease in their ownership respectively.
• Halozyme Therapeutics reported a 40.8% increase in revenue year-over-year, with earnings per share surpassing projections at $1.54 for the latest quarter, exceeding the estimate of $1.23 by $0.31.

111 Capital acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 13,238 shares of the biopharmaceutical company's stock, valued at approximately $689,000.

Other large investors also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC bought a new stake in Halozyme Therapeutics in the first quarter worth $32,000. SVB Wealth LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at about $33,000. Bessemer Group Inc. boosted its holdings in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares during the period. Brooklyn Investment Group grew its position in Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 670 shares during the last quarter. Finally, Park Place Capital Corp grew its position in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after acquiring an additional 182 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $55,285,726.65. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the completion of the transaction, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. This trade represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 128,227 shares of company stock valued at $8,908,195. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Down 3.8%

Shares of NASDAQ:HALO opened at $68.98 on Friday. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The stock has a fifty day simple moving average of $70.45 and a two-hundred day simple moving average of $61.95. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The stock has a market capitalization of $8.07 billion, a price-to-earnings ratio of 15.78, a PEG ratio of 0.38 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company's revenue was up 40.8% on a year-over-year basis. During the same period last year, the company earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price target for the company. Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 2nd. HC Wainwright upped their price objective on shares of Halozyme Therapeutics from $85.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Benchmark increased their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $70.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.